公共医疗保健系统中大隐静脉腔内消融的经济影响
该研究回顾性分析加拿大萨斯喀彻温省公共医疗数据,比较2003-2006年(腔内消融前)与2010-2014年(腔内消融后)大隐静脉干预的使用率和成本。结果显示大隐静脉干预率无显著变化(每年90例 vs 92例,P=0.83),但高位结扎剥脱术成本(每例1965.12美元)高于腔内消融(激光每例1295.08美元,射频每例1410.54美元),年总成本从176861美元降至134525美元(P=0.02)。
要点
- 腔内消融前(2003-2006年)与后(2010-2014年)大隐静脉干预率相似(每年90例 vs 92例,P=0.83)。
- 高位结扎剥脱术每例成本1965.12美元,高于腔内激光(1295.08美元/例)和射频(1410.54美元/例)。
- 大隐静脉干预年总成本从176861美元降至134525美元(P=0.02)。
核心结论
- 公共资助的腔内消融降低了大隐静脉高位结扎剥脱术的使用率和医疗系统成本,每年约减少42000美元,且未增加大隐静脉干预率。
研究设计与样本
- 回顾性分析加拿大萨斯喀彻温省公共医疗行政数据,纳入2003-2014年高位结扎剥脱术病例和2007-2014年大隐静脉腔内消融(激光和射频)病例,将患者分为腔内消融前时代(2003-2006年)和腔内消融后时代(2010-2014年)。
主要发现
- 腔内消融前时代大隐静脉干预率为每年90例,腔内消融后时代为每年92例(P=0.83)。
- 高位结扎剥脱术每例成本为1965.12美元,高于腔内激光的1295.08美元/例和射频的1410.54美元/例。
- 大隐静脉干预年总成本从腔内消融前时代的176861美元降至腔内消融后时代的134525美元(P=0.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In mid-2007, endovenous ablation (EVA) of the great saphenous vein was introduced into the publicly funded health care system in Saskatchewan, Canada. We hypothesize that the introduction of EVA resulted in a decrease in use of high ligation and stripping (HL/S), decreased costs to the health care system, and increased demand of patients for great saphenous vein ablative procedures. METHODS: We retrospectively reviewed administrative data to capture cases of HL/S between 2003 and 2014 and cases of EVA of the great saphenous vein (endovenous laser treatment and radiofrequency ablation) between 2007 and 2014. Accounting for the change in practice pattern that occurred slowly between 2007 and 2009, we divided our patients into the pre-EVA era (2003-2006) and the post-EVA era (2010-2014). Procedure costs were determined with models used by our health region for this purpose. RESULTS: Utilization rates for great saphenous vein intervention remained similar in the pre-EVA (90 procedures per year) and post-EVA (92 procedures per year; P = .83) eras. Case costs of HL/S ($1965.12/case) were higher than those of EVA (endovenous laser treatment, $1295.08/case; radiofrequency ablation, $1410.54/case). The total annual costs of great saphenous vein intervention decreased from $176,861 in the pre-EVA era to $134,525 (P = .02). CONCLUSIONS: Introduction of publicly funded EVA has reduced rates of HL/S and reduced costs to our health system by approximately $42,000 per year, without increasing great saphenous vein intervention rates.
引用
- Butt A, Kopriva D. Economic implications of endovenous great saphenous ablation in a public health care system. J Vasc Surg Venous Lymphat Disord. 2018. PMID: 29602759. doi:10.1016/j.jvsv.2017.12.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。